Research Analysts’ Recent Ratings Changes for Alphatec (ATEC)

A number of research firms have changed their ratings and price targets for Alphatec (NASDAQ: ATEC):

• 3/13/2023 – Alphatec was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 3/1/2023 – Alphatec had its price target raised by analysts at Morgan Stanley from $17.00 to $18.00. They now have an “overweight” rating on the stock.
• 3/1/2023 – Alphatec had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
• 3/1/2023 – Alphatec had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.

Alphatec Trading Down 1.5 %

Shares of NASDAQ:ATEC opened at $15.10 on Thursday. The company has a debt-to-equity ratio of 29.74, a quick ratio of 1.11 and a current ratio of 1.84. The stock’s 50-day moving average is $13.86 and its 200-day moving average is $11.12. The company has a market cap of $1.68 billion, a P/E ratio of -10.27 and a beta of 1.25. Alphatec Holdings, Inc. has a 52-week low of $5.73 and a 52-week high of $16.34.

Insider Buying and Selling

In other Alphatec news, Director James L. L Tullis sold 30,000 shares of the business’s stock in a transaction dated Wednesday, March 8th. The shares were sold at an average price of $16.12, for a total value of $483,600.00. Following the transaction, the director now directly owns 467,974 shares in the company, valued at $7,543,740.88. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, SVP Scott Lish sold 9,570 shares of the company’s stock in a transaction that occurred on Tuesday, February 21st. The stock was sold at an average price of $14.02, for a total transaction of $134,171.40. Following the sale, the senior vice president now owns 465,534 shares in the company, valued at approximately $6,526,786.68. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James L. L. Tullis sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 8th. The shares were sold at an average price of $16.12, for a total value of $483,600.00. Following the completion of the sale, the director now owns 467,974 shares in the company, valued at approximately $7,543,740.88. The disclosure for this sale can be found here. Insiders have sold a total of 721,644 shares of company stock valued at $970,162,115 over the last three months. 33.93% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alphatec

A number of institutional investors and hedge funds have recently bought and sold shares of ATEC. Quantamental Technologies LLC raised its stake in shares of Alphatec by 8.0% in the third quarter. Quantamental Technologies LLC now owns 13,170 shares of the medical technology company’s stock worth $115,000 after purchasing an additional 980 shares during the last quarter. Legal & General Group Plc increased its position in Alphatec by 3.1% in the fourth quarter. Legal & General Group Plc now owns 33,038 shares of the medical technology company’s stock worth $408,000 after buying an additional 994 shares during the last quarter. CIBC Private Wealth Group LLC increased its position in Alphatec by 8.4% in the third quarter. CIBC Private Wealth Group LLC now owns 12,904 shares of the medical technology company’s stock worth $113,000 after buying an additional 1,000 shares during the last quarter. Captrust Financial Advisors boosted its holdings in shares of Alphatec by 5.2% in the second quarter. Captrust Financial Advisors now owns 23,712 shares of the medical technology company’s stock worth $155,000 after acquiring an additional 1,162 shares during the period. Finally, Metropolitan Life Insurance Co NY boosted its stake in Alphatec by 35.8% during the fourth quarter. Metropolitan Life Insurance Co NY now owns 4,508 shares of the medical technology company’s stock valued at $56,000 after buying an additional 1,188 shares during the period. Institutional investors and hedge funds own 48.59% of the company’s stock.

Alphatec Holdings, Inc engages in the design, development, and marketing of spinal fusion technology products and solutions for the treatment of spinal disorders. It offers intra-operative information and neuromonitoring technologies, access systems, interbody implants, fixation systems, and various biologics offerings.